GYRE THERAPEUTICS, INC. 8-K

What Happened Gyre Therapeutics, Inc. (GYRE) filed an 8‑K reporting the results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. As of the April 16, 2026 record date, 96,994,001 shares were entitled to vote. Each Class II director nominee was elected to serve until the 2029 Annual Meeting, and the other proposals on the proxy were approved, including an advisory vote on executive compensation, ratification of the independent auditor, and approval of the conversion of Series B preferred stock.

Key Details

• Record date / Shares entitled to vote: 96,994,001 shares as of April 16, 2026.
• Director elections: David M. Epstein, Ph.D. — 70,160,332 votes for, 354,109 withheld, 1,985,197 broker non‑votes; Dan Weng, M.D. — 70,483,425 for, 31,016 withheld, 1,985,197 broker non‑votes.
• Advisory vote on executive compensation: Approved — 70,478,374 for, 34,907 against, 1,160 abstentions, 1,985,197 broker non‑votes.
• Independent auditor ratified: Grant Thornton Zhitong Certified Public Accountants LLP ratified for 2026 — 72,487,596 for, 11,626 against, 416 abstentions.
• Approval of Series B conversion: Authorized under Nasdaq Rule 5635(a) — 70,497,125 for, 16,031 against, 1,285 abstentions, 1,985,197 broker non‑votes.

Why It Matters These outcomes confirm board continuity (directors re‑elected) and shareholder support for the company’s governance actions, including executive pay (non‑binding) and the planned conversion of Series B preferred stock, which may affect the company’s capital structure once conversions occur. Ratification of the auditor secures continuity for 2026 financial reporting. For investors, the votes signal general shareholder approval of management’s proposals and administrative steps that could be prerequisites for future financings or corporate actions.